Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Gilead Seeks FDA Approval for Hep C Treatment for All Genotypes

Gilead has applied to the FDA for approval of the combo tablet of Sovaldi and velpatasvir to treat those with genotypes 1 through 6 of hepatitis C.

Published
02 November 2015
From
AIDSMeds
'Dallas Buyers' Club' for Hep C treatments under investigation

A "Dallas Buyers Club" of doctors and patients importing potentially life-saving Hepatitis C medication from countries like China is being investigated by the Therapeutic Goods Administration.

Published
22 October 2015
From
Sydney Morning Herald
NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients with Chronic Hepatitis C Genotypes 1, 3 and 4

Bristol-Myers Squibb today announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in England and Wales for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. Specifically, NICE recommended Daklinza, an oral, once-daily medication used in combination with other agents, to treat certain patients with HCV genotypes 1, 3 and 4.

Published
16 October 2015
From
Bristol-Myers Squibb press release
U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs

Three applications are under review for Daklinza in combination with sofosbuvir with or without ribavirin to treat chronic hepatitis C patients with decompensated cirrhosis, post-liver transplant recurrence of HCV, and coinfection with HIV-1.

Published
07 October 2015
From
Bristol-Myers Squibb
Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes

If Approved, SOF/VEL Would be the First All-Oral Pan-Genotypic Single Tablet Regimen for Chronic HCV. U.S. NDA and European MAA Submissions Planned for Q4. 2015.

Published
21 September 2015
From
Gilead press release
Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial Evaluating Odalasvir (ACH-3102) and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

100% SVR12 reported for all patients treated for six- (n=18) or eight-weeks (n=12). Odalasvir (ACH-3102) is the subject of an exclusive, worldwide development and commercialization license granted to Janssen

Published
18 September 2015
From
Achillion press release
Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission

Daklinza in combination with sofosbuvir is the first 12-week all-oral therapy for genotype 3 patients without cirrhosis in Europe.

Published
15 September 2015
From
Bristol-Myers Squibb press release
Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® + EXVIERA® in Genotype 1 Hepatitis C Patients

Interim results from the independent AMBER study demonstrated 98 percent (n=39/40) SVR(12) rate in patients who completed a 12- or 24-week treatment regimen and 12 weeks follow-up.

Published
14 September 2015
From
AbbVie press release
Hepatitis C patients in England denied lifesaving liver drug

Health experts concerned about decision not to extend Daklinza treatment to patients with genotype 3 strain of virus.

Published
18 August 2015
From
The Observer
Medicines Patent Pool At 5 Years: Promises Kept, Changes Ahead – An Interview With Greg Perry

The Medicines Patent Pool in Geneva is celebrating five years of existence this month. MPP Executive Director Greg Perry sat down with Intellectual Property Watch Catherine Saez to describe progress made since its inception, the success of its licensing agreement model, and plans for the future, including a possible extension to other diseases such as tuberculosis and hepatitis C.

Published
04 August 2015
From
Intellectual Property Watch

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close